[go: up one dir, main page]

PL2477648T3 - Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych - Google Patents

Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych

Info

Publication number
PL2477648T3
PL2477648T3 PL10817793.2T PL10817793T PL2477648T3 PL 2477648 T3 PL2477648 T3 PL 2477648T3 PL 10817793 T PL10817793 T PL 10817793T PL 2477648 T3 PL2477648 T3 PL 2477648T3
Authority
PL
Poland
Prior art keywords
therapy
synergistic anti
hematologic cancers
hematologic
cancers
Prior art date
Application number
PL10817793.2T
Other languages
English (en)
Inventor
Irving L. Weissman
Ravindra Majeti
Arash Ash Alizadeh
Mark P. Chao
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43758999&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2477648(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of PL2477648T3 publication Critical patent/PL2477648T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10817793.2T 2009-09-15 2010-09-15 Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych PL2477648T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27672609P 2009-09-15 2009-09-15
PCT/US2010/048992 WO2011034969A1 (en) 2009-09-15 2010-09-15 Synergistic anti-cd47 therapy for hematologic cancers

Publications (1)

Publication Number Publication Date
PL2477648T3 true PL2477648T3 (pl) 2022-11-07

Family

ID=43758999

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10817793.2T PL2477648T3 (pl) 2009-09-15 2010-09-15 Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych

Country Status (9)

Country Link
US (4) US8758750B2 (pl)
EP (2) EP4134095A1 (pl)
AU (1) AU2010295661B2 (pl)
CA (2) CA3057650A1 (pl)
ES (1) ES2927646T3 (pl)
PL (1) PL2477648T3 (pl)
PT (1) PT2477648T (pl)
SI (1) SI2477648T1 (pl)
WO (1) WO2011034969A1 (pl)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072655B2 (en) 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
CA2965198C (en) 2008-01-15 2021-02-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
EP2111869A1 (en) * 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
WO2013023015A2 (en) 2011-08-11 2013-02-14 Albert Einstein College Of Medicine Of Yeshiva University Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes
RS59159B1 (sr) * 2012-02-06 2019-10-31 Inhibrx Inc Cd47 antitela i postupci za njihovu upotrebu
SMT202200295T1 (it) * 2012-05-18 2022-09-14 Aptevo Res & Development Llc Immunofusione bispecifica (bif) di scfv legante cd123 e cd3
DK3725807T3 (da) * 2012-12-03 2026-01-12 Novimmune Sa Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf
SG11201504469XA (en) 2012-12-12 2015-07-30 Vasculox Inc Therapeutic cd47 antibodies
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
US9873747B2 (en) 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
CA2905418C (en) * 2013-03-13 2023-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
EP2970493B1 (en) * 2013-03-15 2019-04-03 The Board of Trustees of the Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents
WO2014186761A2 (en) * 2013-05-17 2014-11-20 The Board Of Trustes Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-cd47 agent
NL2011904C2 (en) * 2013-12-06 2015-06-09 Stichting Vu Vumc Leukemic stem cell markers.
JP6560682B2 (ja) * 2014-01-08 2019-08-14 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 小細胞肺癌に対する標的療法
SG11201607143UA (en) 2014-03-11 2016-09-29 Univ Leland Stanford Junior Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
EP3188758B1 (en) * 2014-08-08 2023-10-04 The Board of Trustees of the Leland Stanford Junior University Sirp alpha-antibody fusion proteins
CN107108748A (zh) 2014-08-15 2017-08-29 默克专利有限公司 SIRPα免疫球蛋白融合蛋白
DK3656869T4 (da) 2014-08-26 2025-05-19 Univ Leland Stanford Junior Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering
CA2964173A1 (en) * 2014-10-10 2016-04-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to eliminate cancer stem cells by targeting cd47
WO2016089692A1 (en) * 2014-12-05 2016-06-09 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 47 gene
MX391051B (es) 2014-12-30 2025-03-21 Celgene Corp Anticuerpos anti-cd47 y usos de los mismos.
AU2016232719A1 (en) * 2015-03-18 2017-10-12 Memorial Sloan Kettering Cancer Center Compositions and methods for targeting CD99 in haematopoietic and lymphoid malignancies
CA2988854A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
US10894831B2 (en) * 2015-08-26 2021-01-19 The Board Of Trustees Of The Leland Stanford Junior University Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
WO2017049251A2 (en) 2015-09-18 2017-03-23 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
HK1257309A1 (zh) 2015-09-21 2019-10-18 Erasmus University Medical Center 抗-cd47抗体及使用方法
DK3380525T3 (da) * 2015-11-25 2024-01-29 Immunogen Inc Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
IL296410A (en) 2015-11-27 2022-11-01 Cartherics Pty Ltd Genetically modified stem cells and uses thereof
US10946042B2 (en) * 2015-12-01 2021-03-16 The Trustees Of The University Of Pennsylvania Compositions and methods for selective phagocytosis of human cancer cells
DK3402820T3 (da) 2016-01-11 2020-05-18 Forty Seven Inc Humaniserede, muse- eller kimære anti-cd47-monoklonale antistoffer
AU2017210224B2 (en) * 2016-01-21 2024-02-08 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents
EP3442593A4 (en) * 2016-04-15 2020-01-01 Trillium Therapeutics Inc. STIMULATION OF MACROPHAGES IN THERAPY BY CD47 BLOCKING
CA3019841A1 (en) 2016-04-29 2017-11-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the prevention and treatment of surgical adhesions
MX389710B (es) 2016-05-27 2025-03-20 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
WO2018014067A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Anti-cd47 combination therapy
EP3494228B1 (en) * 2016-08-03 2021-07-07 CBmed GmbH Center for Biomarker Research in Medicine Method for prognosing and diagnosing tumors
KR20190036528A (ko) 2016-08-03 2019-04-04 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴
PH12019500609B1 (en) 2016-09-21 2024-02-21 Aptevo Res & Development Llc Cd123 binding proteins and related compositions and methods
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
WO2018081448A1 (en) 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
EP3345924A1 (en) 2017-01-10 2018-07-11 Universität Duisburg-Essen Use of cd47 antibodies
WO2018165015A1 (en) 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
PT3642242T (pt) 2017-06-21 2024-04-16 Univ Leland Stanford Junior Parâmetros de dosagem para terapias de direcionamento de cd47 para malignidades hematológicas
EP3661965A4 (en) 2017-08-02 2022-07-13 Phanes Therapeutics, Inc. ANTI-CD47 ANTIBODIES AND USES THEREOF
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
JP7308191B2 (ja) 2017-10-18 2023-07-13 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７剤ベースの卵巣癌療法
JP2021500926A (ja) 2017-11-01 2021-01-14 ハミングバード・バイオサイエンス・ホールディングス・プライベート・リミテッド Ｃｄ４７抗原結合分子
WO2019086574A1 (en) * 2017-11-01 2019-05-09 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 and cd33 antigen-binding molecules
AU2019218271B2 (en) 2018-02-12 2024-12-12 Forty Seven, LLC Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies
CN110305212A (zh) 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
MX2021000614A (es) * 2018-07-17 2021-07-02 Univ California Células diferenciadas de células pluripotentes inmunodiseñadas.
PE20211491A1 (es) 2018-09-27 2021-08-11 Celgene Corp PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP2022506761A (ja) * 2018-10-29 2022-01-17 ティガティーエックス，インコーポレーテッド ＩｇＡ抗体構築物を含む組成物および方法
CR20210272A (es) 2018-11-26 2021-07-14 Forty Seven Inc Anticuerpos humanizados contra c-kit
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
TW202104260A (zh) 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
MX2021013713A (es) 2019-05-10 2021-12-10 Univ California Celulas pluripotentes modificadas.
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
MY209360A (en) * 2019-10-31 2025-07-03 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
CN110755635B (zh) * 2019-11-14 2022-10-11 天津大学 Flu@α-cd47@RGD制剂的合成方法
TW202134280A (zh) * 2019-12-05 2021-09-16 美商索倫多醫療公司 包含抗cd47抗體與腫瘤靶向抗體之組合物及方法
EP4262828A1 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
EP4370542A4 (en) * 2021-07-15 2025-09-17 Vcreate Inc COMPOSITIONS AND METHODS FOR PRODUCING NOVEL T CELL RECEPTORS
WO2023165618A1 (en) * 2022-03-04 2023-09-07 Nanjing University Methods for treating cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
JP3053873B2 (ja) 1994-08-12 2000-06-19 イムノメディクス，インコーポレイテッド Ｂ細胞リンパ腫細胞および白血病細胞に特異的な免疫結合体およびヒト化抗体
AU6873396A (en) 1995-10-16 1997-05-07 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
FR2741892B1 (fr) 1995-12-04 1998-02-13 Pasteur Merieux Serums Vacc Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus
CA2226962A1 (en) * 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2005526044A (ja) * 2002-02-21 2005-09-02 デューク ユニバーシティ 抗ｃｄ２２抗体を使用した治療方法
AU2003294210A1 (en) * 2002-07-31 2004-05-04 Seattle Genetics, Inc Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
WO2005044857A1 (ja) 2003-11-11 2005-05-19 Chugai Seiyaku Kabushiki Kaisha ヒト化抗cd47抗体
WO2007053189A2 (en) 2005-06-01 2007-05-10 Northwestern University Compositions and methods for altering immune function
US20090191202A1 (en) 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
CA2682266A1 (en) 2007-03-28 2008-10-09 Biogen Idec Inc. Treatment of hodgkins lymphoma
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
CA2965198C (en) 2008-01-15 2021-02-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
EP2111869A1 (en) * 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system

Also Published As

Publication number Publication date
ES2927646T3 (es) 2022-11-08
PT2477648T (pt) 2022-10-27
AU2010295661B2 (en) 2015-04-30
EP4134095A1 (en) 2023-02-15
CA3057650A1 (en) 2011-03-24
EP2477648A1 (en) 2012-07-25
US20140369924A1 (en) 2014-12-18
EP2477648A4 (en) 2013-05-08
SI2477648T1 (sl) 2022-09-30
US20210214437A1 (en) 2021-07-15
US8758750B2 (en) 2014-06-24
CA2771336C (en) 2019-11-26
US20120282174A1 (en) 2012-11-08
WO2011034969A1 (en) 2011-03-24
CA2771336A1 (en) 2011-03-24
US20190048075A1 (en) 2019-02-14
AU2010295661A1 (en) 2012-03-22
EP2477648B1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
EP2477648A4 (en) SYNERGISTIC ANTI-CD47 THERAPY FOR HEMATOLOGICAL CANCER
HUS1800001I1 (hu) Kombinációs terápia COPD-hez
PL2440545T3 (pl) Związki użyteczne do leczenia nowotworu
IL206654A0 (en) Combination therapy
PL2440287T3 (pl) Urządzenie do terapii fotodynamicznej
AP3250A (en) Tablets for combination therapy
EP2621497A4 (en) ASSOCIATION TREATMENT FOR ROSE ACNE
PT2957292T (pt) Terapia de vitiligo
AU330856S (en) Safe
GB201013898D0 (en) Well treatment
GB0901465D0 (en) Compounds for use in therapy
GB0707556D0 (en) Treatment for cancer
GB0916997D0 (en) Combination therapy
GB0803948D0 (en) Combination therapy
ZA201201894B (en) Pharmaceutical combination for treating tumor
GB0907973D0 (en) Combination therapy
GB0809046D0 (en) Cancer treatment
GB0913603D0 (en) Cancer therapy
GB0921102D0 (en) Cancer Therapy
GB0901497D0 (en) Compound for therapy
GB0914441D0 (en) Compound for therapy
GB0903080D0 (en) Compound for therapy
GB0903321D0 (en) Therapy
GB0921244D0 (en) Therapy
GB0914820D0 (en) WATerian therapy